The overall goal of the Infectious Disease Assay Development (IDAD) Core is provide expertise, facilities, services, and training in the area of HTS assay design, development, validation, small and large-scale screening for organism (cell) based or biochemical infectious disease targets. Assay development and performing high-throughput screening for infectious disease targets can be very similar to other biological and disease targets; however, there are often specific biological hazards associated with infectious disease targets that can require special consideration and conditions. This core will build upon current assets and expand the current capabilities by providing enabling expertise and dedicated attention of a core director and a technician to the community of infectious disease scientists and their biologically and disease relevant targets. Core staff will facilitate design, development, validation of assays suitable for automated high-throughput chemical screening. They will also facilitate small or large scale screening of compounds (at KU or from external sources). The expected outcomes of this core and associated efforts are well developed and validated assays suitable for automated large-scale screening that can be performed internally or externally. Hits generated through successful assay development and limited or large scale screening efforts will be directed into Core C and Core D to identify lead compounds for use as molecular probes and pre-therapeutics for infectious diseases. The expertise and resources will also enable investigators to develop competitive proposals in response to NIH funding opportunities.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Exploratory Grants (P20)
Project #
5P20GM113117-04
Application #
9706875
Study Section
Special Emphasis Panel (ZGM1)
Project Start
Project End
Budget Start
2019-05-01
Budget End
2020-04-30
Support Year
4
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Kansas Lawrence
Department
Type
DUNS #
076248616
City
Lawrence
State
KS
Country
United States
Zip Code
66045
Denler, Melissa C; Wijeratne, Gayan B; Rice, Derek B et al. (2018) MnIII-Peroxo adduct supported by a new tetradentate ligand shows acid-sensitive aldehyde deformylation reactivity. Dalton Trans 47:13442-13458
Kfoury, Najla; Sun, Tao; Yu, Kwanha et al. (2018) Cooperative p16 and p21 action protects female astrocytes from transformation. Acta Neuropathol Commun 6:12
Roy, Anuradha (2018) Early Probe and Drug Discovery in Academia: A Minireview. High Throughput 7:
Franklin, Meghan Whitney; Nepomnyachiy, Sergey; Feehan, Ryan et al. (2018) Efflux Pumps Represent Possible Evolutionary Convergence onto the ?-Barrel Fold. Structure 26:1266-1274.e2
Mori-Quiroz, Luis M; Hedrick, Sidnee L; De Los Santos, Andrew R et al. (2018) A Unified Strategy for the Syntheses of the Isoquinolinium Alkaloids Berberine, Coptisine, and Jatrorrhizine. Org Lett 20:4281-4284
Franklin, Meghan Whitney; Slusky, Joanna S G (2018) Tight Turns of Outer Membrane Proteins: An Analysis of Sequence, Structure, and Hydrogen Bonding. J Mol Biol 430:3251-3265
Deschamps, Thibaut; Kalamvoki, Maria (2018) Extracellular Vesicles Released by Herpes Simplex Virus 1-Infected Cells Block Virus Replication in Recipient Cells in a STING-Dependent Manner. J Virol 92:
Komiya, Takefumi; Yamamoto, Satomi; Roy, Anuradha et al. (2017) Drug screening to target nuclear orphan receptor NR4A2 for cancer therapeutics. Transl Lung Cancer Res 6:600-610
Cao, Shuai; Realegeno, Susan; Pant, Anil et al. (2017) Suppression of Poxvirus Replication by Resveratrol. Front Microbiol 8:2196
Deschamps, Thibaut; Kalamvoki, Maria (2017) Evasion of the STING DNA-Sensing Pathway by VP11/12 of Herpes Simplex Virus 1. J Virol 91:

Showing the most recent 10 out of 27 publications